Chemotherapy directly into the abdomen after surgery for advanced ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests giving chemotherapy directly into the abdomen (intraperitoneal) after optimal surgery for advanced ovarian cancer. It aims to see if this approach is safe and effective for women who have already received 3-4 cycles of chemotherapy before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Women ages 18 to 70 with advanced ovarian cancer (stage IIIB–IV) confirmed by biopsy
- You must have received 3 or 4 cycles of chemotherapy before surgery (called neoadjuvant chemotherapy)
- Your surgery must have removed all visible cancer (CC-0) and you did not need a bowel reconnection (anastomosis)
- No signs of cancer outside your abdominal cavity, such as in distant lymph nodes
- Your liver, kidneys, and bone marrow must be working well enough (checked by blood tests)
- You cannot be pregnant, nursing, or have had an allergic reaction to cisplatin or paclitaxel
- You must be in good general health (able to do daily activities)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests an intensive treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer. It combines planned surgery to remove visible tumor with chemotherapy that is put directly inside the abdomen during the operation, aiming to control the cancer more effectively.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
This trial tests whether doing surgery with small incisions (minimally invasive) instead of a large cut is safe and effective for advanced ovarian cancer after chemo. It may mean a faster recovery while still removing the cancer.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This Phase 3 trial studies a three-step “extra” chemotherapy plan after surgery for people with certain advanced ovarian, fallopian-tube, or primary peritoneal cancers. The goal is to improve outcomes by lowering the chance the cancer comes back.
This study looks at whether the timing of surgery after chemotherapy can be personalized for advanced ovarian cancer. It uses a blood test (CA125) to help decide the best time for surgery, aiming to improve outcomes.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.